A$0.036 pre-market 07 Apr 2026: CDX.AX CardieX (ASX) oversold bounce potential

We see CDX.AX stock trading A$0.036 in the ASX pre-market on 07 Apr 2026, setting an oversold bounce setup. CardieX Limited (CDX.AX) has a small market cap of A$19,802,891.00 and low liquidity with 176,535 shares traded yesterday. We view the current price as a short-term mean reversion candidate, but fundamentals and a negative yearly forecast require caution. Our analysis frames catalysts, risks, and a practical trading plan for an oversold bounce attempt.

Where CDX.AX stock stands now

CardieX Limited (CDX.AX) opened pre-market at A$0.038 and sits at A$0.036 today. The 52-week range is A$0.027 to A$0.175, and the 50-day average is A$0.03212. Volume yesterday was 176,535, below the 30-day average of 458,209, so moves can be amplified on low flow.

Fundamentals and valuation for CardieX Limited

CardieX reports EPS -0.04 and a PE of -0.90, reflecting trailing losses. Price to sales is 3.15, and price to book is 2.65. Current ratio is 1.56, and debt to equity is 0.66, showing moderate leverage. Revenue per share is 0.01525 and book value per share is 0.01359, so tangible coverage is thin.

Technical setup: oversold bounce case

Price is beneath the 200-day average of A$0.06546, signaling a longer-term downtrend. Short-term, the stock traded as low as A$0.035 today, producing a potential oversold bounce trade. A viable intraday target is a retest of the 50-day average at A$0.03212, and a more aggressive bounce target is A$0.055.

Meyka AI rates CDX.AX with a score out of 100

Meyka AI rates CDX.AX with a score out of 100: the model gives 63.93/100, Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s summary flags short-term mean reversion opportunity but notes weak profitability and low liquidity.

Meyka AI’s forecast and price target outlook

Meyka AI’s forecast model projects a yearly price of A$0.02288. That implies an estimated downside of -36.46% versus the current A$0.036. For an oversold bounce strategy, we show short-term targets at A$0.055 and a medium-term target at A$0.10, with a conservative stop below A$0.027. Forecasts are model-based projections and not guarantees.

Risks, catalysts and trading plan

Key risks include sustained negative earnings, thin volume, and sector weakness in Healthcare. Catalysts are contract wins, clinical trial data, or wearable partnerships. For traders, risk one to two percent of capital per trade, use tight stops, and prefer limit orders. We monitor company announcements at the official site and market flow before scaling in.

Final Thoughts

CDX.AX stock offers an oversold bounce setup in the ASX pre-market at A$0.036, but it is a high-risk idea. Fundamentals show EPS -0.04, PE -0.90, and modest cash per share 0.00590, so any bounce must be validated by news or improved volume. Meyka AI’s forecast model projects A$0.02288 for the year, an implied -36.46% downside versus today, which argues for caution on longer holds. For a tactical oversold bounce, we prefer a short-term target of A$0.055 with a stop under A$0.027, and position sizing to limit losses. This balances a technical bounce opportunity with weak fundamentals. For ongoing updates see CardieX filings at CardieX website and market flows at Investing.com. Meyka AI provides this as an AI-powered market analysis platform, not financial advice. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.